Author, as appears in the article.: Carbonell, R; Moreno, G; Martín-Loeches, I; Bodí, M; Rodríguez, A
Department: Medicina i Cirurgia
URV's Author/s: Rodríguez Oviedo, Alejandro Hugo
Keywords: Ventilator-associated pneumonia Sars-cov-2 Prognostic value Prognosis Procalcitonin concentrations Procalcitonin Marker Lower respiratory-tract Influenza pneumonia Infections Covid-19 Care Calcitonin-i gene C-reactive protein Biomarkers Bacterial respiratory co-infection Antibiotic-therapy
Abstract: Pneumonia is a growing problem worldwide and remains an important cause of morbidity, hospitalizations, intensive care unit admission and mortality. Viruses are the causative agents in almost a fourth of cases of community-acquired pneumonia (CAP) in adults, with an important representation of influenza virus and SARS-CoV-2 pneumonia. Moreover, mixed viral and bacterial pneumonia is common and a risk factor for severity of disease. It is critical for clinicians the early identification of the pathogen causing infection to avoid inappropriate antibiotics, as well as to predict clinical outcomes. It has been extensively reported that biomarkers could be useful for these purposes. This review describe current evidence and provide recommendations about the use of biomarkers in influenza and SARS-CoV-2 pneumonia, focusing mainly on procalcitonin (PCT) and C-reactive protein (CRP). Evidence was based on a qualitative analysis of the available scientific literature (meta-analyses, randomized controlled trials, observational studies and clinical guidelines). Both PCT and CRP levels provide valuable information about the prognosis of influenza and SARS-CoV-2 pneumonia. Additionally, PCT levels, considered along with other clinical, radiological and laboratory data, are useful for early diagnosis of mixed viral and bacterial CAP, allowing the proper management of the disease and adequate antibiotics prescription. The authors propose a practical PCT algorithm for clinical decision-making to guide antibiotic initiation in cases of influenza and SARS-CoV-2 pneumonia. Further well-design studies are needed to validate PCT algorithm among these patients and to confirm whether other biomarkers are indeed useful as diagnostic or prognostic tools in viral pneumonia.
Thematic Areas: Pharmacology, toxicology and pharmaceutics (miscellaneous) Pharmacology, toxicology and pharmaceutics (all) Pharmacology (medical) Pharmacology & pharmacy Microbiology (medical) Microbiology Infectious diseases General pharmacology, toxicology and pharmaceutics Engenharias ii Biochemistry
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: alejandrohugo.rodriguez@urv.cat
Author identifier: 0000-0001-8828-5984
Record's date: 2024-08-03
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.mdpi.com/2079-6382/12/1/161
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Antibiotics. 12 (1):
APA: Carbonell, R; Moreno, G; Martín-Loeches, I; Bodí, M; Rodríguez, A (2023). The Role of Biomarkers in Influenza and COVID-19 Community-Acquired Pneumonia in Adults. Antibiotics, 12(1), -. DOI: 10.3390/antibiotics12010161
Article's DOI: 10.3390/antibiotics12010161
Entity: Universitat Rovira i Virgili
Journal publication year: 2023
Publication Type: Journal Publications